ロード中...
Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment
BACKGROUND: Clozapine is the only licensed medication for treatment-resistant schizophrenia. The metabolism of clozapine is affected by multiple pharmacokinetic interactions, so the co-administration of adjunct medications can have a significant clinical effect. The anti- tuberculosis medication rif...
保存先:
| 出版年: | BMC Psychiatry |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4542109/ https://ncbi.nlm.nih.gov/pubmed/26265348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12888-015-0536-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|